Key result
Clopidogrel plasma levels were inversely correlated with platelet microparticle release (rho=-0.57) and positively correlated with endothelial progenitor cell mobilization in patients with stable coronary artery disease.
Why the study?
Does the combination of atorvastatin and clopidogrel influence endothelial progenitor cell mobilization and platelet microparticle release in patients with stable coronary artery disease?
Population
26 adults with stable coronary artery disease on stable statin therapy for at least 3 months, median age 63…
Comparison
Atorvastatin 80 mg daily and clopidogrel 75 mg… vs Within-subject comparison across different…
Design
Cohort, open-label
Follow-up
3 weeks
Authors
Loading...
Should not yet change clopidogrel prescribing in stable CAD; leaves open whether these correlations reflect causal vascular protection or atorvastatin interaction.
Does the combination of atorvastatin and clopidogrel influence endothelial progenitor cell mobilization and platelet microparticle release in patients with stable coronary artery disease?
Effect estimate: rho=-0.57
p-value: p=0.006
Clopidogrel plasma levels inversely correlate with platelet microparticle release and positively correlate with endothelial progenitor cell mobilization, suggesting a potential vascular protective mechanism in stable CAD.
França et al. (2011) studied Stable coronary artery disease (n=26). Atorvastatin and Clopidogrel vs. Baseline and sequential monotherapy phases was evaluated on Correlation between clopidogrel maximum serum concentration (Cmax) and platelet microparticles (PMP) at visit 3 (rho=-0.57, p=0.006). Clopidogrel plasma levels were inversely correlated with platelet microparticle release (rho=-0.57) and positively correlated with endothelial progenitor cell mobilization in patients with stable coronary artery disease.